CEO Sklawer departs; severance includes $441K lump sum, full equity vesting, $425/hr consulting

Fresh Tracks Therapeutics, Inc.

CEO Andrew Sklawer terminated without cause effective Oct 2, 2023; severance of $441k (12 months base) plus $44k retention bonus.
Accrued PTO paid $165,375; health care premiums for 12 months with 35% gross-up if continued coverage not available.
All unvested equity awards fully vested as of Separation Date; equity exercise extended to 3 years.
Sklawer to provide consulting via Yonder Partners at $425 per hour; contract terminable by either party.
CEO departure in connection with previously disclosed plan to liquidate and dissolve the company.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew D. Sklawer

President and Chief Executive Officer

Fresh Tracks Therapeutics, Inc.

Effective: 2023-10-02
Filed: October 10, 2023, 7:59 PM ET

the Company terminated Andrew D. Sklawer, the Company’s President and Chief Executive Officer, without cause, effective October 2, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew D. Sklawer was terminated as President and Chief Executive Officer at Fresh Tracks Therapeutics, Inc..

Action: terminated
Role: President and Chief Executive Officer

Exact text from the filing

the Company terminated Andrew D. Sklawer, the Company’s President and Chief Executive Officer, without cause, effective October 2, 2023

View on SEC.gov

Source: SEC EDGAR

accession 0001628280-23-034176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.